MCT1-inhibitors impair lactate transport, resulting in a metabolic switch from lactate that fuels OXPHOS to glycolysis, indirectly eliminating tumor cells in the hypoxic region via glucose deprivation. This evidence concerns the gene SLC16A1 and neoplasm.